Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Repeat testing for SARS-COV-2: Persistence of viral RNA is common, and clearance is slower in older age groups

View ORCID ProfilePaulina Stehlik, View ORCID ProfileKylie Alcorn, Anna Jones, View ORCID ProfileSanmarie Schlebusch, Andre Wattiaux, View ORCID ProfileDavid Henry
doi: https://doi.org/10.1101/2020.08.27.20183483
Paulina Stehlik
1Evidence-Based Practice Professorial Unit, Gold Coast University Hospital and Health Service, Southport, Queensland, Australia
2Institute for Evidence-Based Practice, Bond University, Robina, Queensland, Australia
Roles: Senior Research Fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paulina Stehlik
  • For correspondence: pstehlik@bond.edu.au
Kylie Alcorn
3Infectious Diseases Department, Gold Coast University Hospital and Health Service, Southport, Queensland, Australia
Roles: App Sci. Infectious Disease Staff Specialist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kylie Alcorn
Anna Jones
4Pathology Queensland (Gold Coast Microbiology Laboratory), Health Support Queensland, Queensland Health, Southport, Queensland, Australia
Roles: Acting Supervising Scientist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanmarie Schlebusch
5Queensland Health Forensic and Scientific Services, Brisbane, Queensland, Australia
Roles: Principal Clinical Microbiologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanmarie Schlebusch
Andre Wattiaux
6Gold Coast Public Health Unit, Gold Coast University Hospital and Health Service, Carrara, Queensland, Australia
Roles: Medical Director
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Henry
1Evidence-Based Practice Professorial Unit, Gold Coast University Hospital and Health Service, Southport, Queensland, Australia
2Institute for Evidence-Based Practice, Bond University, Robina, Queensland, Australia
Roles: Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Henry
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

OBJECTIVE Queensland’s Novel Coronavirus (SARS-CoV-2) suppression program has been relatively successful. Initially, it involved extensive community testing and repeat sampling of positive individuals for release from isolation. This enabled study of several characteristics, including persistence of detectable virus and how apparent viral clearance rates varied by age and sex.

DESIGN We conducted an exploratory analysis of Queensland Pathology SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) test results. Kaplan Meier analyses were used to estimate median time to apparent viral clearance, and Cox regression to explore the effects of sex and age.

SETTING AND PARTICIPANTS Individuals tested for presence of SARS-CoV-2 in the upper respiratory tract between January 19 and June 4, 2020.

OUTCOME MEASURES Presence of viral RNA detected by RT-PCR.

RESULTS We analyzed 97,476 individuals. Median age was 41y (range <1-105y), and 57.2% (95% CI 57.2, 57.2) were female. In total, 958 (0.98%; 95% CI 0.92,1.05) tested positive for SARS-CoV-2. Positivity rates were lower in regional areas than cities, in females (OR 0.80, 95% CI 0.70, 0.91), and in those aged 16y and below (p<0.01, test for trend).

Of the 958 positive individuals, 243 had two or more (max 17) additional tests, and 92% (95% CI 88.1, 95.2) remained positive after 10 days (max 76 days) after the initial result.

Median time to apparent viral clearance was longer in those 65y and over compared to those under 65y (29 v 43 days, HR 1.85; 95% CI 1.17, 2.90), and was unaffected by sex (HR 0.93; 95% CI 0.66, 1.30).

CONCLUSIONS Females and those 16y and under were less likely to test positive for SARS-CoV-2. Detectable RNA may persist for long periods, negating the value of repeat testing for declaring individuals free of infection. Viral clearance rates appear lower in those over 65y of age compared with younger individuals.

“The known”

  • - Early in the COVID-19 pandemic, 2 negative RT-PCR swabs were used to achieve negative status in infected individuals

  • - There are few published data on the patterns of results seen with repeat testing in Australia.

“The new”

  • - We analysed data from a large cohort of people tested for viral RNA in Queensland

  • - We found that females and those 16 y and under were less likely to test positive.

  • - Viral RNA was detectable for up to 76 days, with >90% testing positive for more than 10 days.

  • - Viral clearance was slower in those over the age of 65.

“The implications”

  • - There is likely to be little value in repeat RT-PCR testing to declare individuals free from infection.

The first Australian cases of infection with SARS-CoV-2 were reported in January 2020.1 During the initial phase the peak daily infection rate was in late March 2020 and by the end of June 2020 there had been around 8000 cases and 104 deaths.2 Initially, the majority of cases were acquired outside the country rather than by local transmission.3 The cumulative incidence rates (June 2020) of around 400/million, and mortality of 4/million, were towards the lower end of the rates that have been experienced in other high-income countries, although these are rising quickly with recent outbreaks in Victoria and New South Wales.3 Rates of infection remain relatively low in Queensland.3

In Queensland, the criteria for testing individuals for SARS-CoV-2 changed during the pandemic. Initially, to be tested in Queensland people were required to meet both epidemiological (return from a high-risk country), and clinical criteria (suggestive symptoms). With progression of the pandemic, testing criteria were modified to clinical criteria only (details provided below).

The rollout of a comprehensive testing program and the availability of data from repeated within-subject testing carried out in the initial stages of the Covid-19 pandemic provided an opportunity to conduct an exploratory study to address several questions. We investigated population testing rates and how they varied over time. We estimated the proportions of individuals who returned positive tests and how these varied with location age and sex. We also estimated apparent rates of clearance of viral RNA from the upper respiratory tract of subjects with repeated tests, and the extent to these varied with age and sex.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Gold Coast Health Human Research Ethics Committee (LNR/2020/QGC/63045)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Original data not available due to privacy; analysis code, description of data structure available at our OSF webpage.

https://osf.io/habvk/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 01, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Repeat testing for SARS-COV-2: Persistence of viral RNA is common, and clearance is slower in older age groups
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Repeat testing for SARS-COV-2: Persistence of viral RNA is common, and clearance is slower in older age groups
Paulina Stehlik, Kylie Alcorn, Anna Jones, Sanmarie Schlebusch, Andre Wattiaux, David Henry
medRxiv 2020.08.27.20183483; doi: https://doi.org/10.1101/2020.08.27.20183483
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Repeat testing for SARS-COV-2: Persistence of viral RNA is common, and clearance is slower in older age groups
Paulina Stehlik, Kylie Alcorn, Anna Jones, Sanmarie Schlebusch, Andre Wattiaux, David Henry
medRxiv 2020.08.27.20183483; doi: https://doi.org/10.1101/2020.08.27.20183483

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1254)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10040)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2473)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1649)
  • Health Policy (756)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11880)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2298)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (457)
  • Occupational and Environmental Health (537)
  • Oncology (1254)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (736)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2288)
  • Public and Global Health (4849)
  • Radiology and Imaging (844)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (653)
  • Rheumatology (287)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)